Ownership Action To Observe: Sentiment Report: Endo Health Solutions Inc (NASDAQ:ENDP)

November 30, 2016 - By Hazel Jackson   ·   0 Comments

Ownership Action To Observe: Sentiment Report: Endo Health Solutions Inc (NASDAQ:ENDP)

Sentiment for Endo Health Solutions Inc (NASDAQ:ENDP)

Endo Health Solutions Inc (NASDAQ:ENDP) institutional sentiment decreased to 0.77 in Q2 2016. Its down -0.18, from 0.95 in 2016Q1. The ratio fall, as 157 funds increased and opened new equity positions, while 166 sold and reduced their stock positions in Endo Health Solutions Inc. The funds in our partner’s database now possess: 192.40 million shares, up from 189.57 million shares in 2016Q1. Also, the number of funds holding Endo Health Solutions Inc in their top 10 equity positions decreased from 7 to 5 for a decrease of 2. Sold All: 76 Reduced: 90 Increased: 115 New Position: 42.

The stock decreased 3.00% or $0.5 during the last trading session, hitting $16.17. Endo International plc – Ordinary Shares (NASDAQ:ENDP) has declined 44.01% since April 27, 2016 and is downtrending. It has underperformed by 49.24% the S&P500.

Analysts await Endo International plc – Ordinary Shares (NASDAQ:ENDP) to report earnings on March, 6. They expect $1.64 EPS, up 20.59% or $0.28 from last year’s $1.36 per share. ENDP’s profit will be $377.29 million for 2.46 P/E if the $1.64 EPS becomes a reality. After $1.01 actual EPS reported by Endo International plc – Ordinary Shares for the previous quarter, Wall Street now forecasts 62.38% EPS growth.

According to Zacks Investment Research, “Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.”

Kamunting Street Capital Management L.P. holds 5.91% of its portfolio in Endo International plc – Ordinary Shares for 164,946 shares. Camber Capital Management Llc owns 5.05 million shares or 3.8% of their US portfolio. Moreover, Tpg Group Holdings (Sbs) Advisors Inc. has 3.79% invested in the company for 22.15 million shares. The New York-based Deltec Asset Management Llc has invested 3.02% in the stock. Monroe Hall Asset Management Llc, a New York-based fund reported 557,366 shares.#img1#

Endo International plc – Ordinary Shares (NASDAQ:ENDP) Ratings Coverage

Ratings analysis reveals 65% of Endo International plc’s analysts are positive. Out of 17 Wall Street analysts rating Endo International plc, 11 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $20 while the high is $100. The stock’s average target of $54.31 is 235.87% above today’s ($16.17) share price. ENDP was included in 38 notes of analysts from August 11, 2015. The rating was downgraded by RBC Capital Markets on Friday, May 6 to “Sector Perform”. The rating was maintained by Stifel Nicolaus on Friday, May 6 with “Buy”. Deutsche Bank initiated Endo International plc – Ordinary Shares (NASDAQ:ENDP) rating on Tuesday, September 29. Deutsche Bank has “Buy” rating and $88 price target. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) has “Overweight” rating given on Monday, March 21 by JP Morgan. The stock has “Neutral” rating given by Piper Jaffray on Friday, May 6. The stock has “Market Perform” rating given by BMO Capital Markets on Wednesday, June 29. The firm has “Outperform” rating by Northland Capital given on Thursday, September 29. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) has “Market Perform” rating given on Wednesday, December 9 by Northland Capital. RBC Capital Markets maintained the shares of ENDP in a report on Wednesday, November 9 with “Outperform” rating. The stock of Endo International plc – Ordinary Shares (NASDAQ:ENDP) earned “Equal Weight” rating by Barclays Capital on Friday, May 6.

ENDP Company Profile

Endo International plc, incorporated on October 31, 2013, is a global specialty pharmaceutical firm focused on developing, manufacturing, marketing and distributing branded and generic pharmaceutical products, as well as over-the-counter medications through its operating companies- Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs and SOMAR. The Company’s divisions include U.S. Branded Pharmaceuticals, which offer portfolio of branded pharmaceuticals such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX; U.S. Generic Pharmaceuticals portfolio consists of tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches, and International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets. It sells generic products primarily in the United States across multiple therapeutic categories.

Another recent and important Endo International plc – Ordinary Shares (NASDAQ:ENDP) news was published by Valuewalk.com which published an article titled: “Endo International plc – Ordinary Shares (ENDP) Collapses Taking Hedge Fund …” on May 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News